| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.YADR.2005.03.002 |
| P698 | PubMed publication ID | 16350447 |
| P2093 | author name string | Susan Burgin | |
| P2860 | cites work | A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome | Q27824793 |
| Clopidogrel-induced systemic inflammatory response syndrome | Q28196023 | ||
| Genetic variations in HLA-B region and hypersensitivity reactions to abacavir | Q28214097 | ||
| Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel | Q28378187 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee | Q29620666 | ||
| Cutaneous manifestations of antiretroviral therapy. | Q30329472 | ||
| Sex differences in nevirapine rash | Q31704898 | ||
| Low molecular weight heparin-induced skin necrosis-a systematic review | Q33363909 | ||
| Heparin-induced thrombocytopenia in the cardiovascular patient: diagnostic and treatment guidelines | Q33364307 | ||
| Mucocutaneous reactions to chemotherapy | Q33539859 | ||
| Lamotrigine-associated rash: risk/benefit considerations in adults and children | Q33685953 | ||
| Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy | Q34102185 | ||
| Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir | Q34117815 | ||
| Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial | Q34271566 | ||
| Acquired and inherited lipodystrophies | Q34306820 | ||
| Coxibs and cardiovascular disease | Q34356732 | ||
| Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial | Q34530459 | ||
| Some common issues in the use of antiepileptic drugs | Q34778740 | ||
| Reactive Metabolites and Adverse Drug Reactions: Clinical Considerations | Q35117318 | ||
| Risk of cardiovascular events and rofecoxib: cumulative meta-analysis | Q45175627 | ||
| Serious dermatologic reaction associated with valdecoxib: report of two cases | Q45176932 | ||
| Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience | Q45711911 | ||
| Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection | Q45751686 | ||
| Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab | Q47733204 | ||
| Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study | Q47771380 | ||
| The experts speak. Metabolic complications associated with HIV infection and antiretroviral therapy. Interview by Vicki Glaser. | Q48652220 | ||
| Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. | Q49029133 | ||
| Complications of therapy and a diagnostic dilemma case. Case 2. Cutaneous toxicity induced by cetuximab. | Q51012349 | ||
| Hypersensitivity reaction in a child due to lamotrigine. | Q54104682 | ||
| Factors Influencing the Incidence of Lamotrigine-Related Skin Rash | Q57274025 | ||
| Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 | Q59571925 | ||
| Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey | Q73428394 | ||
| Acute generalized exanthematous pustulosis following use of ticlopidine | Q73703445 | ||
| Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases | Q74175903 | ||
| Nevirapine-associated Stevens-Johnson syndrome | Q74282325 | ||
| Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern | Q74773160 | ||
| Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody | Q77071974 | ||
| Lamotrigine-associated anticonvulsant hypersensitivity syndrome | Q77441611 | ||
| Etanercept and infliximab associated with cutaneous vasculitis | Q77493682 | ||
| Drug-induced systemic lupus erythematosus and TNF-alpha blockers | Q94077789 | ||
| Extensive fixed drug eruption due to lamotrigine | Q95721471 | ||
| Novel therapies based on mechanisms of HIV-1 cell entry. | Q35139577 | ||
| Imatinib treatment: specific issues related to safety, fertility, and pregnancy | Q35143836 | ||
| Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors | Q35647847 | ||
| Safety of tumour necrosis factor-alpha antagonists | Q35734045 | ||
| Enfuvirtide: a fusion inhibitor for the treatment of HIV infection | Q35756756 | ||
| Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders | Q35785960 | ||
| Indications for imatinib mesylate therapy and clinical management | Q35787974 | ||
| Molecularly targeted treatment for dermatofibrosarcoma protuberans | Q35791279 | ||
| Acute generalized exanthematic pustulosis: a case and an overview of side effects affecting the skin caused by celecoxib and other COX-2 inhibitors reported so far. | Q35827828 | ||
| Cardiovascular toxicity with highly active antiretroviral therapy: review of clinical studies | Q35911374 | ||
| Separate and concomitant use of lamotrigine, lithium, and divalproex in bipolar disorders | Q35946071 | ||
| Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions | Q36053675 | ||
| Dose-dependent severe cutaneous reactions to imatinib | Q37355043 | ||
| Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer | Q40489484 | ||
| Oxcarbazepine and DRESS syndrome: a paediatric cause of acute liver failure | Q40526555 | ||
| DRESS syndrome associated with nevirapine therapy | Q40592786 | ||
| Oral lichenoid reaction to imatinib (STI 571, Gleevec). | Q40635394 | ||
| Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir | Q43527201 | ||
| Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies | Q43658492 | ||
| Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia | Q43732601 | ||
| Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study | Q43797374 | ||
| Fixed drug eruption to rofecoxib with cross-reactivity to sulfonamides | Q43830453 | ||
| Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571. | Q43872808 | ||
| Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study | Q43904522 | ||
| Fatal allergic vasculitis associated with celecoxib | Q43919660 | ||
| Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. | Q43977683 | ||
| Imatinib mesylate and gray hair | Q44094545 | ||
| Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour | Q44099096 | ||
| Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor | Q44122729 | ||
| Pityriasis rosea associated with imatinib (STI571, Gleevec). | Q44129568 | ||
| Rofecoxib-induced instant aquagenic wrinkling of the palms | Q44130643 | ||
| Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia | Q44216050 | ||
| Safety of celecoxib in individuals allergic to sulfonamide: a pilot study | Q44311321 | ||
| Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients | Q44312442 | ||
| Valdecoxib-induced toxic epidermal necrolysis in a patient allergic to sulfa drugs | Q44393546 | ||
| Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial | Q44438587 | ||
| Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. | Q44469168 | ||
| Onycholysis and subungual haemorrhages secondary to systemic chemotherapy (paclitaxel). | Q44496792 | ||
| Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide | Q44630719 | ||
| Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management | Q44643260 | ||
| Imatinib mesylate causes hypopigmentation in the skin | Q44667131 | ||
| Cutaneous injection site reactions to long-term therapy with enfuvirtide. | Q44777349 | ||
| Inflammation of actinic keratoses during capecitabine therapy | Q44801296 | ||
| Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study | Q44820677 | ||
| Skin reaction to adalimumab | Q44898233 | ||
| Incidence of rash and discontinuation of nevirapine using two different escalating initial doses | Q45013023 | ||
| P304 | page(s) | 279-302 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | Advances in dermatology | Q26839851 |
| P1476 | title | New drugs, new rashes: update on cutaneous drug reactions | |
| P478 | volume | 21 |
Search more.